PacificGMP president and chief scientific officer Leigh Pierce said, "Vasgene’s novel technology shows tremendous promise for a vital area of therapeutic need, and we at PacificGMP are honored to have supported their effort by optimizing, scaling and manufacturing their human clinical trial material."
PacificGMP vice president of Operations Kristin DeFife said, "Using our 500 liter capacity Wave bioreactor platform, we produced and subsequently purified enough of Vasgene’s recombinant fusion protein to aseptically fill over 2500 vials."
Vasgene co-founder and director Parkash Gill said "We selected PacificGMP as our Contract Manufacturing Organization because of their considerable expertise in scale-up and cGMP manufacturing of proteins using single use technology as well as for their commitment to being a partner in our efforts to bring this product to the clinic."
PacificGMP is a contract manufacturer and a provider of single-use technology for development and manufacturing of biologics, while Vasgene is a clinical-stage company dedicated to the development and commercialization of innovative therapeutics based on the understanding of vascular biology.